Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for breast cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
7 Why do I have a family history of cancer? There are three reasons why you might have a family history of cancer: Just by chance Breastcancer is a common disease. This means that many people have several people in their family who have developed breastcancer by coincidence. Environmental factors Many families live in similar environments, so they often share similar diets and lifestyles. These non-inherited factors may influence the chance of developing cancer. Inherited factors An inherited (...) Understanding genetic tests for breast and ovarian cancer that runs in the family Understanding genetic tests for breast and ovarian cancer that runs in the family Information and decision aidPublished May 2008 Reprinted January 2014 Current print February 2018 This booklet was developed and printed with the support of: Hereditary Cancer Clinic, Prince of Wales Hospital Macquarie University Centre for Genetics Education, NSW Health, Royal North Shore Hospital Cancer Council NSW Understanding
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative BreastCancers The aim of the current study was to conduct a pooled analysis of studies that have investigated the prognostic value of tumor-infiltrating lymphocytes (TILs) in early-stage triple negative breastcancer (TNBC).Participating studies had evaluated the percentage infiltration of stromally located TILs (sTILs) that were quantified in the same manner in patient diagnostic (...) samples of early-stage TNBC treated with anthracycline-based chemotherapy with or without taxanes. Cox proportional hazards regression models stratified by trial were used for invasive disease-free survival (iDFS; primary end point), distant disease-free survival (D-DFS), and overall survival (OS), fitting sTILs as a continuous variable adjusted for clinicopathologic factors.We collected individual data from 2,148 patients from nine studies. Average age was 50 years (range, 22 to 85 years), and 33
studies demonstrate stimulation of breastcancer cells by estriol. 96 Estriol is not FDA approved for any indication. Vaginal laser The FDA has approved laser therapy for several medical indications (eg, refractive eye surgery, dental procedures, tumor and cataract removal, cosmetic surgery). Available data suggest that inducing morphologic changes in vaginal tissue with laser intervention can alleviate the symptoms of vaginal dryness and dyspareunia accompanying GSM. 97-103 (...) ,womenwithestrogen-receptorpositive breastcancers, women with triple-negative breastcancers, and women with metastatic disease. Key Words: Atrophic vaginitis – Breastcancer – Breastcancer risk – Breastcancer survivors – Genitourinary syndrome of menopause – Vulvovaginal atrophy. Received March 21, 2018; revised and accepted March 22, 2018. Menopause, Vol. 25, No. 6, 2018 1 Copyright 2018 The North American Menopause Society. Unauthorized reproduction of this article is prohibited. Menopause: The Journal
arrangement. Wh Why the committee made these recommendations y the committee made these recommendations Palbociclib or ribociclib, taken with an aromatase inhibitor, are usually the first treatments for locally advanced or metastatic, hormone receptor-positive, HER2-negative breastcancer. They are cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors, as is abemaciclib. Clinical trial evidence shows that abemaciclib with an aromatase inhibitor increases how long people live without their disease getting (...) receptor (HER2)-negative breastcancer is usually a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor, currently palbociclib or ribociclib, with an aromatase inhibitor (letrozole or anastrozole). The committee noted that since the CDK 4/6 inhibitors have been recommended, not many patients have an aromatase inhibitor alone. If symptoms are severe or the disease is rapidly progressive, then chemotherapy may be needed in the first instance, and tamoxifen can also be offered to some people in line
Accuracy of Self-report for Cervical and BreastCancer Screening Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Evidence Brief: Accuracy of Self-report for Cervical and BreastCancer Screening Health Services Research & Development Evidence Brief: Accuracy of Self-report for Cervical and BreastCancer Screening to the ESP Report RSS feed Prepared by: Evidence Synthesis Program (ESP) Coordinating (...) Center Portland VA Health Care System Portland, OR Mark Helfand, MD, MPH, MS, Director Recommended Citation: Anderson J, Bourne D, Peterson, K, Mackey K. Evidence Brief: Accuracy of Self-report for Cervical and BreastCancer Screening. VA ESP Project #09-199; 2019. Download PDF: , Purpose The ESP Coordinating Center (ESP CC) is responding to a request from the VHA Performance Workgroup for an evidence brief on the accuracy of patient self-report for cervical and breastcancer screening. Findings from
, metastasis), morphology, grade, estrogen receptor and progesterone receptor (PR), human epidermal growth factor receptor 2, and molecular subtype.Women with T2D (n = 1,567) were more often diagnosed with a more advanced tumor stage (odds ratio 1.28 [95% CI 13-1.44]) and a higher grade (1.22 [1.08-1.39]) though less often with a PR-negative breasttumor (0.77 [0.67-0.89]) than women without diabetes (n = 6,267). No associations were found for the other breastcancer characteristics. Women with T2D using (...) Cancer Registry-PHARMO Database Network (N = 33,377). T2D was defined as receiving two or more dispensings of noninsulin blood glucose-lowering drugs prior to breastcancer diagnosis. Women with T2D were matched to women without diabetes. Among women with T2D, insulin users and nonusers were compared. Multivariable ordinal logistic regression was used to investigate the association between T2D/insulin and breastcancer characteristics, including TNM classification (tumor size, lymph node status
for metastatic triple-negative breastcancer. The end points included safety; the objective response rate (according to Response Evaluation Criteria in Solid Tumors, version 1.1), which was assessed locally; the duration of response; the clinical benefit rate (defined as a complete or partial response or stable disease for at least 6 months); progression-free survival; and overall survival. Post hoc analyses determined the response rate and duration, which were assessed by blinded independent central (...) Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative BreastCancer. Standard chemotherapy is associated with low response rates and short progression-free survival among patients with pretreated metastatic triple-negative breastcancer. Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), with SN-38, which is conjugated to the antibody by a cleavable linker
Surgical interventions for the prevention or treatment of lymphoedema after breastcancer treatment. Breastcancer is the most common type of cancer amongst women worldwide, and one distressing complication of breastcancer treatment is breast and upper-limb lymphoedema. There is uncertainty regarding the effectiveness of surgical interventions in both the prevention and management of lymphoedema affecting the arm after breastcancer treatment.1. To assess and compare the efficacy of surgical (...) interventions for the prevention of the development of lymphoedema (LE) in the arm after breastcancer treatment.2. To assess and compare the efficacy of surgical interventions for the treatment of established LE in the arm after breastcancer treatment.We searched the Cochrane BreastCancer Group's Specialised Register, the Cochrane Central Register of Controlled Trials, MEDLINE, Embase, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), the WHO International Clinical Trials Registry
with taxane following anthracycline to people with early breastcancer receiving chemotherapy. The studies needed to have reported on at least one of our outcomes of interest, which included overall survival, disease-free survival, pathological response, treatment adherence, toxicity and quality of life.Two review authors independently extracted data, assessed risk of bias and quality of the evidence. The primary outcome measure was overall survival. Secondary outcomes included disease-free survival (...) in overall survival (HR 0.80, 95% CI 0.60 to 1.08; 947 participants; 2 studies; moderate-certainty evidence) and disease-free survival (HR 0.84, 95% CI 0.65 to 1.09; 828 participants; 1 study; moderate-certainty evidence). Administration of taxanes first also resulted in little to no difference in pathological complete response (absence of cancer in the breast and axilla: RR 1.15, 95% CI 0.96 to 1.38; 1280 participants; 4 studies; high-certainty evidence). However, there appeared to be a trend in favour
chemotherapy were similar and highly significant (p<0·0001) in oestrogen receptor (ER)-positive and ER-negative disease and did not differ significantly by other patient or tumour characteristics.Increasing the dose intensity of adjuvant chemotherapy by shortening the interval between treatment cycles, or by giving individual drugs sequentially rather than giving the same drugs concurrently, moderately reduces the 10-year risk of recurrence and death from breastcancer without increasing mortality from (...) (RRs).Individual patient data were provided for 26 of 33 relevant trials identified, comprising 37 298 (93%) of 40 070 women randomised. Most women were aged younger than 70 years and had node-positive disease. Total cytotoxic drug usage was broadly comparable in the two treatment arms; colony-stimulating factor was generally used in the more dose-intense arm. Combining data from all 26 trials, fewer breastcancer recurrences were seen with dose-intense than with standard-schedule chemotherapy (10
The impact of intravenous dexamethasone on the efficacy and duration of analgesia of paravertebral block in breastcancer surgery: a randomized controlled trial The study aimed at the evaluation of the impact of intravenous (IV) dexamethasone on efficacy and duration of analgesia of paravertebral block (PVB) in patients undergoing modified radical mastectomy (MRM).This randomized, double-blind controlled trial included 50 patients with breastcancer scheduled for unilateral MRM. Ultrasound (...) ). The VAS scores were significantly lower in Group DB compared to Group B up to 12 hours postoperatively. Morphine consumption was lower in Group DB compared to Group B. PONV Impact Scale score was significantly higher in Group B.Systemic dexamethasone increased the efficacy and duration of the single-shot multilevel PVB in breastcancer surgery.ISRCTN registry, study ID: ISRCTN15920148.
, previous tamoxifen use, and lowest bone mineral density T score in the lumbosacral spine, total hip, or femoral neck. The primary endpoint was disease-free survival, defined as time from randomisation to breastcancer recurrence, second primary malignancy, or death, and was analysed by intention to treat. To adjust for previous interim analyses, the two-sided statistical significance level for disease-free survival was set at 0·0418. This study is registered with ClinicalTrials.gov, number NCT00382070 (...) Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breastcancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial The optimal duration of extended therapy with aromatase inhibitors in patients with postmenopausal breastcancer is unknown. In the NSABP B-42 study, we aimed to determine whether extended letrozole treatment improves disease-free survival after 5 years of aromatase inhibitor-based therapy in women with postmenopausal
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early BreastCancer: PALLET Trial CDK4/6 inhibitors are used to treat estrogen receptor (ER)-positive metastatic breastcancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized trial that evaluated the effects of combination palbociclib plus letrozole as neoadjuvant therapy.Postmenopausal women with ER-positive primary BC and tumors greater (...) ; complete response + partial response, 54.3% v 49.5%), and progressive disease was 3.2% versus 5.4%, respectively. Median log-fold change in Ki-67 was greater with palbociclib plus letrozole compared with letrozole (-4.1 v -2.2; P < .001) in the 190 evaluable patients (61.9%), corresponding to a geometric mean change of -97.4% versus -88.5%. More patients on palbociclib plus letrozole achieved complete cell-cycle arrest (90% v 59%; P < .001). Median log-fold change (suppression) of cleaved poly (ADP
Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive BreastCancer: A Randomized Phase II Trial To evaluate endocrine activity in terms of ovarian function suppression (OFS) of degarelix (a gonadotropin-releasing hormone [GnRH] antagonist) versus triptorelin (a GnRH agonist) in premenopausal patients receiving letrozole as neoadjuvant endocrine therapy for breast cancer.Premenopausal women with stage cT2 to 4b, any N (...) , M0; estrogen receptor and progesterone receptor greater than 50%; human epidermal growth factor receptor 2-negative breastcancer were randomly assigned to triptorelin 3.75 mg administered intramuscularly on day 1 of every cycle or degarelix 240 mg administered subcutaneously (SC) on day 1 of cycle 1 then 80 mg SC on day 1 of cycles 2 through 6, both with letrozole 2.5 mg/day for six 28-day cycles. Surgery was performed 2 to 3 weeks after the last injection. Serum was collected at baseline, after
Effectiveness of a precast adjustable compression system compared to multilayered compression bandages in the treatment of breastcancer-related lymphoedema: a randomized, single-blind clinical trial To compare the effectiveness of a precast adjustable compression system with that of multilayered compression bandages in the treatment of breastcancer-related lymphoedema.Multicenter, randomized, single-blind parallel-group clinical trial.The rehabilitation services of four general university (...) hospitals.Patients with upper limb breastcancer-related lymphoedema.All the patients received manual lymphatic drainage, followed by a precast adjustable compression system or multilayered compression bandages, according to the group allocation. The treatment included 10 consecutive sessions over a two-week period from Monday to Friday, followed by some sessions on three alternate days per week, until the patient received a tailored compression garment.The patients were evaluated just before the treatment
; 2012. NICE. ES 15. London: National Institute for Health and Care Excellence; 2017. Jin A, Cobb J, Hansen U, et al. Bone Joint Res. 2017;6(10):602-9. Bisphosphonates and other bone agents for breastcancer Published on 31 October 2017 O'Carrigan, B.,Wong, M. H.,Willson, M. L.,Stockler, M. R.,Pavlakis, N.,Goodwin, A. Cochrane Database Syst Rev Volume 10 , 2017 BACKGROUND: Bone is the most common site of metastatic disease associated with breastcancer (BC). Bisphosphonates inhibit osteoclast (...) , bisphosphonates reduce the risk of developing SREs, delay the median time to an SRE, and appear to reduce bone pain compared to placebo or no bisphosphonate. Expert commentary Like most UK women diagnosed in recent years, my breastcancer was “early” (in my case, stage 1). This Cochrane review does not persuade me to take bisphosphonates. First, following successful evidence-based treatment, I already have a greater than 99% chance of being disease-free in 10 years. My chance of ever developing bone
Delaying chemotherapy after breastcancer surgery may reduce survival chances Delaying chemotherapy after breastcancer surgery may reduce survival chances Discover Portal Discover Portal Delaying chemotherapy after breastcancer surgery may reduce survival chances Published on 31 January 2017 doi: Delaying chemotherapy after breastcancer surgery may slightly decrease a woman’s chances of survival. A review found about a 5% increase in the relative risk of death. Many women are offered (...) chemotherapy soon after breastcancer surgery, called adjuvant chemotherapy. Chemotherapy is usually started after the surgical wounds have healed but the effect of any delay to this was unclear. These researchers calculated the risk from outcomes for almost 30,000 women treated with adjuvant chemotherapy, from studies in Europe and North America. The absolute risk of death for any woman will depend on her individual cancer stage and characteristics. A four week delay could add several percentage points
and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). More than 90% of breastcancers are not metastatic at the time of diagnosis. For people presenting without metastatic disease, therapeutic goals are tumor eradication and preventing recurrence. Triple-negative breastcancer is more likely to recur than the other 2 subtypes, with 85% 5 (...) -year breastcancer-specific survival for stage I triple-negative tumors vs 94% to 99% for hormone receptor positive and ERBB2 positive. Systemic therapy for nonmetastatic breastcancer is determined by subtype: patients with hormone receptor-positive tumors receive endocrine therapy, and a minority receive chemotherapy as well; patients with ERBB2-positive tumors receive ERBB2-targeted antibody or small-molecule inhibitor therapy combined with chemotherapy; and patients with triple-negative tumors
Nomogram for predicting the overall survival of patients with inflammatory breastcancer: A SEER-based study. Inflammatory breastcancer (IBC) is a rare malignancy that is a unique biologic subtype of breastcancer. A nomogram to predict the overall survival (OS) of IBC patients is lacking. The aim of the study was to construct and validate a nomogram to predict the OS of IBC patients based on the Surveillance, Epidemiology, and End Results (SEER) Program.Patients diagnosed with IBC between (...) analysis identified that race, age at diagnosis, breastcancer subtype, grade, N stage, M stage, radiation, chemotherapy, and surgery were significant prognostic factors for the OS. The internally and externally validated Harrell's C-indexes were 0.763 and 0.786, respectively. The calibration plots for predictions of the 1-, 3-, and 5-year OS were in excellent agreement.A nomogram was constructed to predict the OS for IBC patients based on the SEER database and to provide accurate and individualised